Published in Eur Heart J on April 15, 2008
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe) | NCT00386061
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. Int J Obes (Lond) (2011) 1.25
The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 1.24
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol (2012) 1.20
Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A (2008) 1.15
CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem (2010) 1.15
CB1 antagonists for obesity--what lessons have we learned from rimonabant? Nat Rev Endocrinol (2009) 1.12
Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension (2008) 1.07
Impact of treating the metabolic syndrome on chronic kidney disease. Nat Rev Nephrol (2009) 0.96
Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95
The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol (2011) 0.94
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler Thromb Vasc Biol (2009) 0.90
Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Am J Physiol Endocrinol Metab (2013) 0.86
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. Sci Rep (2015) 0.83
Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol (2012) 0.82
Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care (2009) 0.82
Acute overactive endocannabinoid signaling induces glucose intolerance, hepatic steatosis, and novel cannabinoid receptor 1 responsive genes. PLoS One (2011) 0.80
Leptin levels are negatively correlated with 2-arachidonoylglycerol in the cerebrospinal fluid of patients with osteoarthritis. PLoS One (2015) 0.79
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol (2013) 0.79
Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice. PLoS One (2011) 0.78
Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.78
Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controls. Int J Endocrinol (2014) 0.78
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. Eur Heart J (2008) 0.76
Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. Eur J Pharmacol (2014) 0.76
Rimonabant, gastrointestinal motility and obesity. Curr Neuropharmacol (2012) 0.75
The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism. Pharmaceuticals (Basel) (2010) 0.75
Mechanisms underlying restoration of hepatic insulin sensitivity with CB1 antagonism in the obese dog model. Adipocyte (2013) 0.75
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. Int J Neuropsychopharmacol (2016) 0.75
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes. Cell Stress Chaperones (2016) 0.75
Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc Med J (2011) 0.75
Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 7.24
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol (2012) 4.13
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med (2012) 3.15
Does excess pregnancy weight gain constitute a major risk for increasing long-term BMI? Obesity (Silver Spring) (2007) 2.22
Association of weight gain in infancy and early childhood with metabolic risk in young adults. J Clin Endocrinol Metab (2006) 2.15
Long-term weight development in women: a 15-year follow-up of the effects of pregnancy. Obes Res (2004) 2.09
Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. BMJ (2009) 2.06
[High-fat diet intake can be questioned]. Lakartidningen (2008) 2.05
Upward weight percentile crossing in infancy and early childhood independently predicts fat mass in young adults: the Stockholm Weight Development Study (SWEDES). Am J Clin Nutr (2006) 1.99
Associations between physical activity and fat mass in adolescents: the Stockholm Weight Development Study. Am J Clin Nutr (2005) 1.70
Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation (2004) 1.56
[A teetotaller rejected by alcohol ignition interlock]. Lakartidningen (2006) 1.39
TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J (2006) 1.34
Initial weight loss is the best predictor for success in obesity treatment and sociodemographic liabilities increase risk for drop-out. Patient Educ Couns (2010) 1.25
Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care (2007) 1.24
Evolution of analytical performance in portable glucose meters in the last decade. Diabetes Care (2003) 1.19
Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol (2007) 1.18
Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia (2013) 1.13
Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity. Circulation (2004) 1.10
Natural course of gestational diabetes mellitus: long term follow up of women in the SPAWN study. BJOG (2002) 1.09
Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.07
Interrelationships between weight development and weight retention in subsequent pregnancies: the SPAWN study. Acta Obstet Gynecol Scand (2003) 1.06
Comment on Tsuda et al. Poor glycemic control is a major factor in the overestimation of glomerular filtration rate in diabetic patients. Diabetes care 2014;37:596-603. Diabetes Care (2014) 1.06
Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J (2004) 0.99
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients. Obes Res (2002) 0.94
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs (2014) 0.92
Are sexual dissatisfaction and sexual abuse associated with obesity? A population-based study. Obes Res (2004) 0.92
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). Am J Clin Nutr (2003) 0.92
Managing obesity--from childhood and onwards. Int J Pediatr Obes (2011) 0.91
Practical clinical behavioral treatment of obesity. Patient Educ Couns (2003) 0.91
Impact of social support intensity on walking in the severely obese: a randomized clinical trial. Obesity (Silver Spring) (2008) 0.90
TFAP2B influences the effect of dietary fat on weight loss under energy restriction. PLoS One (2012) 0.89
Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. Pharmacol Res (2005) 0.89
TCF7L2 rs7903146-macronutrient interaction in obese individuals' responses to a 10-wk randomized hypoenergetic diet. Am J Clin Nutr (2009) 0.88
Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes. J Diabetes Complications (2013) 0.86
Erythrocyte membrane phospholipid composition is related to hyperinsulinemia in obese nondiabetic women: effects of weight loss. Metabolism (2002) 0.86
Education and supervision of health care professionals to initiate, implement and improve management of obesity. Patient Educ Couns (2005) 0.86
The future of obesity: new drugs versus lifestyle interventions. Expert Opin Investig Drugs (2008) 0.85
Sphingomyelin/cholesterol ratio: an important determinant of glucose transport mediated by GLUT-1 in 3T3-L1 preadipocytes. Cell Signal (2003) 0.85
Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care (2004) 0.85
Locus of control and weight reduction. Patient Educ Couns (2005) 0.85
Obesity management: what brings success? Therap Adv Gastroenterol (2013) 0.84
Metabolically healthy overweight and obesity. Ann Intern Med (2014) 0.84
Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS One (2007) 0.83
Perioperative outcomes after totally robotic gastric bypass: a prospective nonrandomized controlled study. Am J Surg (2013) 0.82
[Alternative causes of obesity]. Ugeskr Laeger (2006) 0.82
Vision and eating behavior. Obes Res (2002) 0.82
Aspirin and clopidogrel resistance in patients with diabetes mellitus. Eur Heart J (2006) 0.82
Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis. Am J Clin Nutr (2005) 0.81
Sympathetic-leptin relationship in obesity: effect of weight loss. Metabolism (2008) 0.81
Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa. Nephron Clin Pract (2008) 0.81
Nutritional models of foetal programming and nutrigenomic and epigenomic dysregulations of fatty acid metabolism in the liver and heart. Pflugers Arch (2013) 0.81
Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J Clin Pharmacol (2015) 0.80
Microstructure of eating behavior associated with Rorschach characteristics in obesity. J Pers Assess (2003) 0.80
Impaired response of cardiac autonomic nervous system to glucose load in severe obesity. Metabolism (2005) 0.80
The change in eating behaviors in a Web-based weight loss program: a longitudinal analysis of study completers. J Med Internet Res (2014) 0.80
Squatting amplifies pulse pressure increase with disease duration in patients with type 1 diabetes. Diabetes Care (2007) 0.80
Squatting test: A posture to study and counteract cardiovascular abnormalities associated with autonomic dysfunction. Auton Neurosci (2011) 0.80
New Year's resolutions to lose weight--dreams and reality. Obes Facts (2011) 0.79
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J (2002) 0.79
The significance of overweight and obesity for individual health behaviour: an economic analysis based on the Swedish surveys of living conditions 1980-81, 1988-89, and 1996-97. Scand J Public Health (2006) 0.79
Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data. Obes Res (2003) 0.79
Are all glitazones the same? Diabetes Metab Res Rev (2002) 0.79
Prevalence of obesity and abdominal obesity in Swedish primary care and occupational health clinics. Obes Facts (2008) 0.79
Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity (Silver Spring) (2008) 0.78
The cause of obesity: are we barking up the wrong tree? Obes Rev (2004) 0.78
Pharmacotherapy of obesity. Clin Dermatol (2004) 0.78
Subgrouping in obesity based on Rorschach personality characteristics. Scand J Psychol (2003) 0.77
A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther (2014) 0.77
Impact of android overweight or obesity and insulin resistance on basal and postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities. Atherosclerosis (2009) 0.77
Diet and physical activity interventions in severely obese adults. JAMA (2011) 0.77
[Nonsurgical management of obesity in adults]. Presse Med (2010) 0.76
Obesity in Europe - does anybody care? Expert Opin Pharmacother (2013) 0.76
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgrad Med (2015) 0.76
[Easy to remain overweight after pregnancy]. Lakartidningen (2003) 0.76
[Weight reduction as treatment of urinary incontinence]. Lakartidningen (2009) 0.75
Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents. Diabetes Care (2002) 0.75
Platelet dysfunction associated with insulin therapy in patients with type 2 diabetes: please do not throw the baby out with the bathwater! J Am Coll Cardiol (2007) 0.75
Pulsatile stress in middle-aged patients with type 1 or type 2 diabetes compared with nondiabetic control subjects. Diabetes Care (2010) 0.75
VALUE: analysis of results. Lancet (2004) 0.75
Progression of the prevalence of metabolic syndrome in normal-weight US subjects. Arch Intern Med (2009) 0.75
Effects of fibrates on cardiovascular outcomes. Lancet (2010) 0.75
Serum plant sterols and atherosclerosis: is there a place for statin-ezetimibe combination? J Am Coll Cardiol (2006) 0.75
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. Eur Heart J (2007) 0.75
[Water--no support for the "8x8 rule"]. Lakartidningen (2008) 0.75
Acarbose for type 2 diabetes prevention. Lancet (2002) 0.75
The safety of obesity drugs. Expert Opin Drug Saf (2007) 0.75
[Multiple risk factors and drug interactions leading to severe lactic acidosis]. Therapie (2008) 0.75
[Prevention of cardiovascular diseases]. Rev Med Suisse (2007) 0.75
Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. Drug Saf (2004) 0.75
[What goals in diet therapy for obesity and/or type 2 diabetes?]. Soins (2004) 0.75
[Don't forget about heart disease in women]. Rev Med Suisse (2008) 0.75
[From the very valuable therapy, to the high cost of a new drug: a growing hiatus]. Rev Med Suisse (2005) 0.75